- Stelios Papadopoulos To Become Chairman of the Board -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Idec (NASDAQ: BIIB) announced today that Chairman of the Board
William D. (Bill) Young will retire from the Company’s Board of
Directors, effective at the Company’s 2014 annual meeting of
stockholders. Mr. Young has been a member of Biogen Idec’s Board of
Directors since 1997 and has served as Chairman of the Board since 2010.
“Bill’s leadership and dedication to Biogen Idec cannot be overstated.
The integrity and determination that he brought to this organization
serve as a benchmark for future leaders to follow,” said George A.
Scangos, Ph.D., chief executive officer of Biogen Idec. “On behalf of
the Board of Directors and Biogen Idec, I would like to thank Bill for
his long-standing service and wish him the best for the future.”
Reflecting on his years on the Biogen Idec Board, Mr. Young said: “I
want to thank the employees of Biogen Idec, whose dedication to science
and devotion to the mission have made a tremendous impact on the lives
of the patients we serve. I expect a very bright future for Biogen Idec
as this mission continues.”
Stelios Papadopoulos, Ph.D., a member of Biogen Idec’s Board of
Directors since 2008, has been appointed to assume the role of Chairman
of the Board following the end of Mr. Young’s term. Dr. Papadopoulos is
the former Vice Chairman of Cowen & Co. LLC and is the current Chairman
of the Board at Exelixis, Inc., a drug discovery company that he
cofounded in 1994, and at Regulus Therapeutics, Inc. Dr. Papadopoulos is
also currently a member of the Board of Directors of BG Medicine, Inc.
“Bill took over as chairman at a difficult time for the company, went on
to unify the Board, spearheaded the recruitment of a new management team
and presided over a time of unprecedented growth for the company. His
record will be hard to match,” said Dr. Papadopoulos
About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers,
develops and delivers to patients worldwide innovative therapies for the
treatment of neurodegenerative diseases, hemophilia and autoimmune
disorders. Founded in 1978, Biogen Idec is the world’s oldest
independent biotechnology company. Patients worldwide benefit from its
leading multiple sclerosis therapies. For product labeling, press
releases and additional information about the Company, please visit www.biogenidec.com.
Kate Niazi-Sai, +1-781-464-3260
Prowse, Ph.D., +1-781-464-2442
Source: Biogen Idec